These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 31501565)

  • 1. Protected rituximab aims at brain metastases.
    Bendayan R
    Nat Biomed Eng; 2019 Sep; 3(9):678-679. PubMed ID: 31501565
    [No Abstract]   [Full Text] [Related]  

  • 2. Sustained delivery and molecular targeting of a therapeutic monoclonal antibody to metastases in the central nervous system of mice.
    Wen J; Wu D; Qin M; Liu C; Wang L; Xu D; Vinters HV; Liu Y; Kranz E; Guan X; Sun G; Sun X; Lee Y; Martinez-Maza O; Widney D; Lu Y; Chen ISY; Kamata M
    Nat Biomed Eng; 2019 Sep; 3(9):706-716. PubMed ID: 31384008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New monoclonal antibody approved as lymphoma therapy.
    Am J Health Syst Pharm; 1998 Jan; 55(2):110. PubMed ID: 9465971
    [No Abstract]   [Full Text] [Related]  

  • 4. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.
    Feugier P
    Future Oncol; 2015; 11(9):1327-42. PubMed ID: 25952779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for bone lymphoma.
    Savage DG; Staron R
    Ann Intern Med; 2001 Jun; 134(12):1156-7. PubMed ID: 11412072
    [No Abstract]   [Full Text] [Related]  

  • 6. 20 years of rituximab treatment: what have we learnt?
    Renner C
    Future Oncol; 2019 Dec; 15(36):4119-4121. PubMed ID: 31718346
    [No Abstract]   [Full Text] [Related]  

  • 7. Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma.
    Errante D; Bernardi D; Bianco A; De Nardi S; Salvagno L
    Ann Oncol; 2006 Nov; 17(11):1720-1. PubMed ID: 16731537
    [No Abstract]   [Full Text] [Related]  

  • 8. Effectiveness of rituximab for chemotherapy-resistant multiple tumoral B-LPD in a haemopoietic stem cell recipient.
    Imashuku S; Naya M; Tamura S; An B; Teramura T; Kobayashi M; Nomura K; Taniwaki M
    Br J Haematol; 2002 Jun; 117(3):771-3. PubMed ID: 12028061
    [No Abstract]   [Full Text] [Related]  

  • 9. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma.
    Dillman RO
    J Clin Oncol; 2002 Aug; 20(16):3545-57. PubMed ID: 12177115
    [No Abstract]   [Full Text] [Related]  

  • 10. Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab.
    Ku M; Chong G; Hawkes EA
    Blood Rev; 2017 Jan; 31(1):23-35. PubMed ID: 27568879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NICE announces guidelines for use of rituximab.
    Mayor S
    BMJ; 2003 Oct; 327(7418):766. PubMed ID: 14525854
    [No Abstract]   [Full Text] [Related]  

  • 12. The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.
    Smolewski P; Robak T
    Expert Opin Drug Discov; 2015 Jul; 10(7):791-808. PubMed ID: 26083358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical observation of Rituximab in a CD20+B non-Hodgkin's lymphoma].
    Hao LC; Zhang LZ
    Zhonghua Er Ke Za Zhi; 2003 Aug; 41(8):627. PubMed ID: 14744396
    [No Abstract]   [Full Text] [Related]  

  • 14. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
    Tobinai K
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab for BCL-2-positive cancers.
    Boughton B
    Lancet Oncol; 2003 Feb; 4(2):69. PubMed ID: 12573343
    [No Abstract]   [Full Text] [Related]  

  • 16. Effective therapeutic use of rituximab in refractory Wegener's granulomatosis.
    Ferraro AJ; Day CJ; Drayson MT; Savage CO
    Nephrol Dial Transplant; 2005 Mar; 20(3):622-5. PubMed ID: 15735243
    [No Abstract]   [Full Text] [Related]  

  • 17. Factors predicting the response to rituximab in indolent lymphoma.
    Lee D
    Clin Lymphoma; 2003 Jun; 4(1):19-21. PubMed ID: 12837149
    [No Abstract]   [Full Text] [Related]  

  • 18. The rapidly expanding role of rituximab in the treatment of aggressive B-cell lymphoma.
    Cooper D
    Cancer J; 2002; 8(5):364-6. PubMed ID: 12416891
    [No Abstract]   [Full Text] [Related]  

  • 19. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.
    Ben Abdelwahed R; Donnou S; Ouakrim H; Crozet L; Cosette J; Jacquet A; Tourais I; Fournès B; Gillard Bocquet M; Miloudi A; Touitou V; Daussy C; Naud MC; Fridman WH; Sautès-Fridman C; Urbain R; Fisson S
    Invest Ophthalmol Vis Sci; 2013 May; 54(5):3657-65. PubMed ID: 23611989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of rituximab maintenance therapy.
    Vose JM
    Clin Adv Hematol Oncol; 2007 Dec; 5(12):968-9,1006. PubMed ID: 18277958
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.